Mifobate

SKU: orb1220103

Description

Mifobate is a potent and specific antagonist of PPARγ. Mifobate shows antiobesity, antidiabetic and antiatherosclerotic effects[1].SR-202 is a new synthetic PPARgamma antagonist,which inhibits both TZD-stimulated recruitment of the coactivator steroid receptor coactivator-1 and TZD-induced transcriptional activity of the receptor. In cell culture, SR-202 efficiently antagonizes hormone- and TZD-induced adipocyte differentiation[1].In vivo, decreasing PPARgamma activity, either by treatment with SR-202 or by invalidation of one allele of the PPARgamma gene, leads to a reduction of both high fat diet-induced adipocyte hypertrophy and insulin resistance. These effects are accompanied by a smaller size of the adipocytes and a reduction of TNFalpha and leptin secretion. Treatment with SR-202 also dramatically improves insulin sensitivity in the diabetic ob/ob mice.

Key Properties

• CAS Number: 76541-72-5
• MW: 358.65
• Purity: >98% (HPLC)
• Formula: C₁₁H₁₇ClO₇P₂
• SMILES: COP(=O)(OC)OC(C1=CC=C(Cl)C=C1)P(=O)(OC)OC
• Target: PPAR
• Solubility: H2O:35.87 mg/mL (100.01 mM; Need ultrasonic and warming)

Bioactivity

• In Vivo:
  Animal model: Eight-week-old male ob/ob mice. Dosage: 400 mg/kg. Administration: Feed (food admixture maintained for 20 days). Result: Prevented the time-dependent increase in glucose concentrations.
  Read more...

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

SR-202

Quick Database Links

Gene Symbol

PPAR